A de novo AML with a t(1;21)(p36;q22) in an elderly patient

A de novo Reciprocal X; 9 Translocation in A Patient with Premature Ovarian Failure

DELETION OF CHROMOSOME 9p22 AS THE SOLE CYTOGENETIC ABNORMALITY IN A PATIENT WITH DE NOVO AML

The diagnostic karyotype of acute leukemia can be used to identify biologically distinct subsets of this heterogeneous disease. Chromosome 9p rearrangement accounts for approximately 10% of adult acute lymphoblastic leukemia (ALL). However, to our knowledge, there has been no report of acute myeloid leukemia (AML) with deletion of 9p22 as the sole cytogenetic abnormality. We here describe a nov...

a de novo reciprocal x; 9 translocation in a patient with premature ovarian failure

0

Bone marrow necrosis in de novo AML.

A 49-year-old man was admitted due to fever, arthralgia, and diarrhea of unknown origin. He had received highly active antiretroviral therapy treatment since 2006, with HIV-RNA being undetectable. Hemogram revealed macrocytic anemia (hemoglobin, 10.5 g/dL; mean corpuscular volume, 101 fL), leukopenia (2.4 G/L; lymphocytes, 2.2 G/L; neutrophils, 0.14 G/L; monocytes, 0.04 G/L; eosinophils, 0.01 G...

Reasons for treating secondary AML as de novo AML.

In a Danish bi-regional registry-based study, we conducted an analysis of the incidence and clinical importance of secondary acute myeloid leukaemia (AML). In a total of 630 cases of AML, we found 157 (25%) cases of secondary AML. The secondary leukaemia arose from MDS (myelodysplastic syndrome) in 77 cases (49%), CMPD (chronic myeloproliferative disorder) in 43 cases (27%) and was therapy-rela...